UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
(Mark
One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended March 31, 2024
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from __________ to__________
Commission
file number: 001-41031
Bluejay
Diagnostics, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware | | 47-3552922 |
(State or Other Jurisdiction of Incorporation or Organization) | | (I.R.S. Employer Identification No.) |
360 Massachusetts Avenue, Suite 203, Acton, MA | | 01720 |
(Address of Principal Executive Offices) | | (Zip Code) |
(844)
327-7078
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically if any, every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files). Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller
reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer | ☐ | Accelerated Filer | ☐ |
Non-Accelerated Filer | ☒ | Smaller Reporting Company | ☒ |
| Emerging Growth Company | ☒ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock | | BJDX | | The Nasdaq Capital Market LLC |
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The
registrant had 2,904,448 shares of common stock outstanding at May 1, 2024.
TABLE
OF CONTENTS
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
We
make forward-looking statements under the “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
and in other sections of this Quarterly Report on Form 10-Q (this “Form 10-Q”). In some cases, you can identify these statements
by forward-looking words such as “may,” “might,” “should,” “would,” “could,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology.
These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections
of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only
predictions based on our current expectations and projections about future events. There are important factors that could cause our actual
results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements
expressed or implied by the forward-looking statements.
While
we believe we have identified material risks, these risks and uncertainties are not exhaustive. Other sections of this Form 10-Q may
describe additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive
and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and
uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors,
may cause actual results to differ materially from those contained in any forward-looking statements.
Although
we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of
activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness
of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We are
under no duty to update any of these forward-looking statements after the date of this Form 10-Q to conform our prior statements to actual
results or revised expectations, and we do not intend to do so.
We
caution you not to place undue reliance on the forward-looking statements, which speak only as of the date of this Form 10-Q in the case
of forward-looking statements contained in this Form 10-Q.
You
should not rely upon forward-looking statements as predictions of future events. Our actual results and financial condition may differ
materially from those indicated in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary
statements. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or achievements. Therefore, you should not rely on any of the forward-looking statements.
In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
EXPLANATORY
NOTE
In
this Form 10-Q, and unless the context otherwise requires, the “Company,” “we,” “us,” and “our”
refer to Bluejay Diagnostics, Inc. and its wholly owned subsidiary Bluejay SpinCo, LLC, taken as a whole.
PART
I - FINANCIAL INFORMATION
Item
1. Condensed Consolidated Financial Statements.
Bluejay
Diagnostics, Inc.
Condensed
Consolidated Balance Sheets
(Unaudited)
| |
March 31, 2024 | | |
December 31, 2023 | |
ASSETS | |
| | |
| |
Current assets: | |
| | |
| |
Cash and cash equivalents | |
$ | 2,661,169 | | |
$ | 2,208,516 | |
Prepaid expenses and other current assets | |
| 788,578 | | |
| 747,263 | |
Deferred offering costs | |
| - | | |
| 265,081 | |
Total current assets | |
| 3,449,747 | | |
| 3,220,860 | |
| |
| | | |
| | |
Property and equipment, net | |
| 1,301,460 | | |
| 1,285,741 | |
Operating lease right-of-use assets | |
| 298,655 | | |
| 333,267 | |
Other non-current assets | |
| 25,215 | | |
| 28,663 | |
Total assets | |
$ | 5,075,077 | | |
$ | 4,868,531 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 271,825 | | |
$ | 491,474 | |
Operating lease liability, current | |
| 145,811 | | |
| 162,990 | |
Accrued expenses and other current liabilities | |
| 1,108,105 | | |
| 1,116,911 | |
Total current liabilities | |
| 1,525,741 | | |
| 1,771,375 | |
| |
| | | |
| | |
Operating lease liability, non-current | |
| 170,703 | | |
| 189,987 | |
Other non-current liabilities | |
| 11,407 | | |
| 12,321 | |
Total liabilities | |
| 1,707,851 | | |
| 1,973,683 | |
| |
| | | |
| | |
Commitments and Contingencies (See Note 13) | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ equity: | |
| | | |
| | |
Common stock, $0.0001 par value; 7,500,000 shares authorized; 2,688,448 and 1,239,140 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | |
| 269 | | |
| 124 | |
Additional paid-in capital | |
| 32,646,412 | | |
| 29,845,714 | |
Accumulated deficit | |
| (29,279,455 | ) | |
| (26,950,990 | ) |
Total stockholders’ equity | |
| 3,367,226 | | |
| 2,894,848 | |
Total liabilities and stockholders’ equity | |
$ | 5,075,077 | | |
$ | 4,868,531 | |
See accompanying notes to condensed consolidated financial statements.
Bluejay
Diagnostics, Inc.
Condensed
Consolidated Statements of Operations
(Unaudited)
| |
Three
Months Ended March 31 | |
| |
2024 | | |
2023 | |
Operating expenses: | |
| | |
| |
Research and development | |
$ | 1,334,797 | | |
$ | 1,354,549 | |
General and administrative | |
| 1,086,884 | | |
| 1,176,977 | |
Sales and marketing | |
| 6,424 | | |
| 148,046 | |
Total operating expenses | |
| 2,428,105 | | |
| 2,679,572 | |
| |
| | | |
| | |
Operating loss | |
| (2,428,105 | ) | |
| (2,679,572 | ) |
| |
| | | |
| | |
Other income: | |
| | | |
| | |
Other income, net | |
| 99,640 | | |
| 139,729 | |
Total other income | |
| 99,640 | | |
| 139,729 | |
| |
| | | |
| | |
Net loss | |
$ | (2,328,465 | ) | |
$ | (2,539,843 | ) |
| |
| | | |
| | |
Net loss per share - Basic and diluted | |
$ | (0.99 | ) | |
$ | (2.49 | ) |
| |
| | | |
| | |
Weighted average common shares outstanding: | |
| | | |
| | |
Basic and diluted | |
| 2,359,376 | | |
| 1,018,755 | |
See accompanying notes to condensed consolidated
financial statements.
Reflects a 1-for-20 reverse stock split effective
July 24, 2023.
Bluejay
Diagnostics, Inc.
Condensed
Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)
| |
Stockholders’ Equity | |
| |
Common Stock | | |
Additional
Paid-In | | |
Accumulated | | |
Total
Stockholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Equity | |
Balance at December 31, 2023 | |
| 1,239,140 | | |
$ | 124 | | |
$ | 29,845,714 | | |
$ | (26,950,990 | ) | |
$ | 2,894,848 | |
Stock-based compensation expense | |
| - | | |
| - | | |
| 11,874 | | |
| - | | |
| 11,874 | |
Issuance of Common Stock and PreFunded Warrants net of issuance costs of $444,950 | |
| 712,538 | | |
| 71 | | |
| 2,788,898 | | |
| - | | |
| 2,788,969 | |
Exercise of PreFunded Warrants | |
| 736,770 | | |
| 74 | | |
| (74 | ) | |
| - | | |
| - | |
Net loss | |
| - | | |
| - | | |
| - | | |
| (2,328,465 | ) | |
| (2,328,465 | ) |
Balance at March 31, 2024 | |
| 2,688,448 | | |
$ | 269 | | |
$ | 32,646,412 | | |
$ | (29,279,455 | ) | |
$ | 3,367,226 | |
| |
Stockholders’ Equity | |
| |
Common Stock | | |
Additional
Paid-In | | |
Accumulated | | |
Total
Stockholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Equity | |
Balance at December 31, 2022 | |
| 1,010,560 | | |
$ | 101 | | |
$ | 28,538,274 | | |
$ | (16,997,102 | ) | |
$ | 11,541,273 | |
Stock-based compensation expense | |
| - | | |
| - | | |
| 54,730 | | |
| - | | |
| 54,730 | |
Grants of fully vested restricted stock units to settle accrued bonus, net of shares withheld | |
| 12,188 | | |
| 1 | | |
| 107,234 | | |
| - | | |
| 107,235 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| (2,539,843 | ) | |
| (2,539,843 | ) |
Balance at March 31, 2023 | |
| 1,022,748 | | |
$ | 102 | | |
$ | 28,700,238 | | |
$ | (19,536,945 | ) | |
$ | 9,163,395 | |
See accompanying notes to condensed consolidated
financial statements.
Reflects a 1-for-20 reverse stock split effective
July 24, 2023.
Bluejay
Diagnostics, Inc.
Condensed
Consolidated Statements of Cash Flows
(Unaudited)
| |
Three Months Ended March 31, | |
| |
2024 | | |
2023 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | |
| |
Net Loss | |
$ | (2,328,465 | ) | |
$ | (2,539,843 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation expense | |
| 19,714 | | |
| 120,017 | |
Stock-based compensation expense | |
| 11,874 | | |
| 219,589 | |
Amortization of right-of-use asset | |
| 34,612 | | |
| 40,328 | |
Non-cash interest expense for finance lease | |
| 294 | | |
| - | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Deferred offering costs | |
| 265,081 | | |
| - | |
Prepaid expenses and other current assets | |
| (41,315 | ) | |
| (446,532 | ) |
Other non-current assets | |
| 3,448 | | |
| 1,768 | |
Accounts payable | |
| (219,649 | ) | |
| (314,773 | ) |
Other non-current Liabilities | |
| (20,492 | ) | |
| - | |
Accrued expenses and other current liabilities | |
| (21,178 | ) | |
| (14,161 | ) |
Net cash used in operating activities | |
| (2,296,076 | ) | |
| (2,933,607 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Purchase of property and equipment | |
| (35,433 | ) | |
| (340,669 | ) |
Net cash used in investing activities | |
| (35,433 | ) | |
| (340,669 | ) |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Proceeds from issuance of common stock, gross | |
| 3,500,000 | | |
| - | |
Payment of issuance costs of common stock | |
| (445,950 | ) | |
| - | |
Payment of deferred offering costs | |
| (265,081 | ) | |
| - | |
Payment of finance lease | |
| (4,807 | ) | |
| (1,202 | ) |
Payment of tax withholding obligations on restricted stock units | |
| - | | |
| (57,601 | ) |
Net cash provided in financing activities | |
| 2,784,162 | | |
| (58,803 | ) |
| |
| | | |
| | |
Increase (decrease) in cash and cash equivalents | |
| 452,653 | | |
| (3,333,079 | ) |
Cash and cash equivalents, beginning of period | |
| 2,208,516 | | |
| 10,114,990 | |
Cash and cash equivalents, end of period | |
$ | 2,661,169 | | |
$ | 6,781,911 | |
| |
| | | |
| | |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH FINANCING ACTIVITIES | |
| | | |
| | |
Liabilities incurred for the purchase of property and equipment | |
| - | | |
$ | 67,000 | |
See accompanying notes to condensed consolidated
financial statements.
Bluejay
Diagnostics, Inc.
Notes
to the Condensed Consolidated Financial Statements
(Unaudited)
1.
NATURE OF OPERATIONS AND BASIS OF PRESENTATION
Business
Bluejay
Diagnostics, Inc. (“Bluejay” or the “Company”) is a medical diagnostics company developing rapid tests using
whole blood on our Symphony technology platform (“Symphony”) to improve patient outcomes in critical care settings. The Company’s
Symphony platform is a combination of Bluejay’s intellectual property (“IP”) and exclusively licensed and patented
IP that consists of a mobile device and single-use test cartridges that if cleared, authorized, or approved by the U.S. Food and Drug
Administration (the “FDA”), can provide a solution to a significant market need in the United States. Clinical trials indicate
the Symphony device produces results in less than 20 minutes for intensive care units and emergency rooms, where rapid and reliable results
are required.
Bluejay’s
first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. IL-6 is a clinically established
inflammatory biomarker, considered a ‘first-responder,’ for assessment of severity of infection and inflammation across many
disease indications, including sepsis. A current challenge of healthcare professionals is the excessive time and cost associated determining
a patient’s level of severity at triage and the Symphony IL-6 test has the ability to consistently monitor this critical care biomarker
with rapid results.
In
the future Bluejay plans to develop additional tests for Symphony including two cardiac biomarkers (hsTNT and NT pro-BNP), as well as
other tests using the Symphony platform. The Company does not yet have regulatory clearance for its Symphony products, and its Symphony
products will need to receive regulatory authorization from the FDA in order to be marketed as a diagnostic product in the United States.
We
were incorporated under the laws of Delaware on March 20, 2015. Our headquarters is located in Acton, Massachusetts.
On
June 4, 2021, the Company formed Bluejay Spinco, LLC, a wholly owned subsidiary of the Company, for purposes of further development of
the Company’s ALLEREYE diagnostic test. ALLEREYE is a point-of-care device offering healthcare providers a solution for diagnosing
Allergic Conjunctivitis.
FDA
Regulatory and Clinical Trial Update
Our current regulatory
strategy is designed to support commercialization of Symphony in the United States pending marketing authorization from the FDA. Previously,
our regulatory strategy involved clinical studies involving COVID-19 patients. However, we have shifted our focus away from COVID-19 patients
due to a significant decline in the number of COVID-19 related hospitalizations. Pursuant to this revised strategy, we are in the process
of completing a pilot clinical study (SYMON-1) and plan to begin clinical study (SYMON-2) to
validate the results of the pilot study to support an FDA regulatory submission with an initial indication for risk stratification of
hospitalized sepsis patients. We submitted a pre-submission application to the FDA presenting the new study design in May 2023 and participated
in a pre-submission meeting on August 11, 2023. At the meeting, the FDA provided feedback on the new study design, determined that the
submission of a 510(k) is the appropriate premarket submission pathway, and requested that certain data be provided in the 510(k). Based
on this feedback, we determined to proceed on this basis, which considers the FDA’s feedback.
In
the first quarter of 2024, we initiated multicenter SYmphony IL-6 MONitoring Sepsis (“SYMON”) clinical studies investigating
the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock. This prospective study aims to assess the performance
of IL-6 upon initial presentation to the intensive care unit (ICU). A preliminary analysis of the SYMON-I pilot clinical study (registered
clinical trial number NCT06181604) highlighted that baseline levels of IL-6 are strongly associated with both in-hospital (40 survivors,
7 non-survivors) and 28-day mortality (31 survivors, 7 non-survivors) among sepsis patients. In contrast, baseline Sequential Organ Failure
Assessment (SOFA) score which is used to assess organ dysfunction in sepsis patients did not predict in-hospital or 28-day mortality.
We believe that the findings underscore the potential importance of IL-6 as a predictor and provide new insights into the potential pathways
for improving sepsis outcomes.
Following
these results, we are planning next steps in our clinical study process, which include a final analysis of the SYMON-I clinical study
dataset upon completion of the study. Subject to our ability to remain a going concern, we intend to present the data at a future national
scientific meeting and publish in peer-reviewed publications. The final results from the SYMON-I clinical study would inform the SYMON-II
validation study, which we would plan to use to support a 510(k) application, which we are targeting for submission in 2025.
Risks
and Uncertainties
The
Company is subject to a number of risks similar to other companies in its industry, including rapid technological change, competition
from larger biotechnology companies and dependence on key personnel. The Company is also impacted by inflationary pressures and global
supply chain disruptions currently impacting many companies.
Our
common stock currently is listed for quotation on the Nasdaq Capital Market. We are required to meet specified financial requirements
in order to maintain such listing, including a requirement that the bid price for our common stock remain above $1.00, and that the market
value of our publicly held securities be at least $1 million.
On
February 28, 2024, we received a notification letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”)
notifying us that the closing bid price for our common stock had been below $1.00 for the previous 30 consecutive business days and that
we therefore are not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under
Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of our common stock on the Nasdaq Capital Market.
Under
the Nasdaq Listing Rules, we have a period of 180 calendar days to regain compliance. To regain compliance, the closing bid price of
our common stock must be at least $1.00 or higher for a minimum of ten consecutive business days, and in such case, Nasdaq will provide
us with written confirmation of compliance. If we do not regain compliance by August 26, 2024, we may be eligible for an additional 180
calendar days, provided that we meet the continued listing requirement for market value of publicly held shares and all other initial
listing standards for Nasdaq, except the bid price requirement. If we are not eligible or it appears to Nasdaq that we will not be able
to cure the deficiency during the second compliance period, Nasdaq will provide written notice to us that our common stock will be subject
to delisting. In the event of such notification, we may appeal Nasdaq’s determination to delist its securities, but there can be
no assurance that Nasdaq would grant our request for continued listing.
We
intend to take all reasonable measures available to us to achieve compliance to allow for continued listing on the Nasdaq Capital Market.
However, there can be no assurance that we will be able to regain compliance with the minimum bid price requirement or will otherwise
be in compliance with other Nasdaq listing criteria. If our common stock does not regain compliance with the minimum price requirement
during the applicable compliance period, we may need to effect a reverse stock split, whereby shares of our common stock are consolidated
so that the per-share trading price becomes greater than $1.00 per share. At our annual meeting of stockholders on May 14, 2024, our
shareholders provided our Board of Directors with authority to implement such a reverse stock split, and our Board of Directors is currently
evaluating whether and when to implement such a reverse stock split.
As of the close of business on May 9, 2024, the
market value of our publicly held common stock (which is our only outstanding class of securities) was approximately $1.25 million. If
the value of our publicly held common stock declines below $1 million, we would also be subject to Nasdaq delisting proceedings on that
basis.
If
our common stock is delisted, we may seek to have our common stock quoted on an over-the-counter marketplace, such as on the OTCQX. The
OTCQX is not a stock exchange, and if our common stock trades on the OTCQX rather than a securities exchange, there may be significantly
less trading volume and analyst coverage of, and significantly less investor interest in, our common stock, which may lead to lower trading
prices for our common stock.
Any
potential delisting of our common stock from the Nasdaq Capital Market may have materially adverse consequences to our stockholders,
including:
|
● |
A reduced market price
and liquidity with respect to our shares of common stock, which could make our ability to raise new investment capital more difficult; |
|
|
|
|
● |
limited dissemination of
the market price of our common stock; |
|
|
|
|
● |
limited news coverage; |
|
|
|
|
● |
limited interest by investors
in our common stock; |
|
|
|
|
● |
volatility of the prices
of our common stock, due to low trading volume; |
|
|
|
|
● |
our common stock being
considered a “penny stock,” which would result in broker-dealers participating in sales of our common stock being subject
to the regulations set forth in Rules 15g-2 through 15g-9 promulgated under the Exchange Act; |
|
|
|
|
● |
increased difficulty in
selling our common stock in certain states due to “blue sky” restrictions; and |
|
|
|
|
● |
limited ability to issue
additional securities or to secure additional financing. |
On July 24, 2023, the Company executed a reverse stock split of its
shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”), with a corresponding reduction in the number of
authorized outstanding number of shares of common stock from 100,000,000 to 7,500,000. The Reverse Stock Split became effective on July
24, 2023. All of the Company’s 2023 historical share and per share information related to issued and outstanding common stock and
outstanding options and warrants exercisable for common stock in these financial statements have been adjusted, on a retroactive basis,
to reflect this 1-for-20 reverse stock split.
Going Concern Uncertainty
The accompanying unaudited condensed consolidated
financial statements for the three months ended March 31, 2024 and 2023 were prepared under the assumption that the Company will continue
as a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course
of business.
Our
operations to date have been funded primarily through
the proceeds of (i) our initial public offering (the “IPO”) in November 2021 (the “IPO Date”), (ii) the registered
direct offering of common stock and concurrent private placement of warrants that we completed on August 28, 2023, and (iii) the public
offering of common stock and warrants that we completed on January 2, 2024. As of March 31, 2024, the Company possessed cash and cash
equivalents of approximately $2.7 million, while having current liabilities of approximately $1.5 million. During the quarter ended March
31, 2024, the Company’s net cash used in operating activities was approximately $2.3 million. The Company expects that it will need
to raise a material amount of additional capital in the imminent near-term to continue its operations, and that absent such near-term
funding, it will likely run out of available cash resources in the near-term. The Company’s board of directors has been exploring
potential pathways for material financing, or other strategic alternatives, and to date, the board of directors has not been able to identify
alternatives that it believes to be viable. If the Company is unable to obtain financing in the
imminent future, the Company’s board of directors could determine to cause the Company to undertake a process of liquidation under
Chapter 7 of applicable U.S. bankruptcy laws. In such event, the Company does not currently expect that holders of shares of common stock
of the Company would recoup any material value in such process.
Basis
of Presentation
The
accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with generally accepted
accounting principles in the United States (“US GAAP”) consistent with those applied in, and should be read in conjunction
with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2023 included in the Company’s
Annual Report on Form 10-K. The unaudited condensed consolidated financial statements reflect all adjustments, which include only normal
recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2024, its results
of operations and cash flows for the three months ended March 31, 2024 and 2023, in accordance with US GAAP. The unaudited condensed
consolidated financial statements do not include all of the information and footnotes required by US GAAP for complete financial statements,
as allowed by the relevant U.S. Securities and Exchange Commission (“SEC”) rules and regulations; however, the Company believes
that its disclosures are adequate to ensure that the information presented is not misleading. The condensed consolidated financial statements
include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated
in consolidation.
The
results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the fiscal year
ending December 31, 2024, or any other interim period within this fiscal year.
2.
SIGNIFICANT ACCOUNTING POLICIES
During
the three months ended March 31, 2024, there were no changes to the significant accounting policies as described in the 2023 Audited
Financial Statements.
Use
of estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
amounts and disclosures reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ
materially from those estimates. The Company believes judgment is involved in accounting for the fair value-based measurement of stock-based
compensation, accruals, and warrants. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future
events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those
differences could be material to the condensed consolidated financial statements.
Stock-based
compensation
Stock-based compensation expense for all stock-based
payment awards made to employees, directors and non-employees is measured based on the grant-date fair value of the award. Stock-based
compensation expense for awards granted to non-employees is determined using the fair value of the consideration received or the fair
value of the equity instruments issued, whichever is more reliably measured.
The Company uses the Black-Scholes option pricing
model to determine the fair value of options granted. The Company recognizes the compensation cost of stock-based awards on a straight-line
basis over the requisite service period. For stock awards for which vesting is subject to performance-based milestones, the expense is
recorded over the implied service period after the point when the achievement of the milestone is probable, or the performance condition
has been achieved.
The Company recognizes forfeitures related to
employee stock-based payments when they occur. Forfeited options are recorded as a reduction to stock compensation expense.
Research
and development expenses
Costs
incurred in the research and development of new products are expensed as incurred. Research and development costs include, but are not
limited to, salaries, benefits, stock-based compensation, laboratory supplies, fees for professional service providers and costs associated
with product development efforts, including preclinical studies and clinical trials.
The
Company estimates preclinical study and clinical trial expenses based on the services performed, pursuant to contracts with research
institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf.
Segment
Reporting
Management
has determined that the Company has one operating segment, which is consistent with the Company structure and how it manages the business.
As of March 31, 2024 and December 31, 2023, the majority of the Company’s assets were located in the United States.
Net
Loss per Share
Basic
net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the
period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by
the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using
the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, convertible
notes, options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference
in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would
be antidilutive.
Potentially
dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti -dilutive are as follows
(in common stock equivalent shares):
Potentially Dilutive Securities Listing: | |
March 31, | |
| |
2024 | | |
2023 | |
Options to purchase common stock | |
| 29,770 | | |
| 36,992 | |
Restricted stock units (RSUs) | |
| 1,000 | | |
| 9,875 | |
Warrants for common stock | |
| 271,714 | | |
| 40,594 | |
Class A warrants for common stock | |
| 124,200 | | |
| 124,200 | |
Class B warrants for common stock | |
| 3,770 | | |
| 3,770 | |
5-Year warrants for common stock | |
| 2,692,308 | | |
| - | |
Prefunded warrants for common stock | |
| 1,243,000 | | |
| - | |
Recently
Adopted Accounting Standards
In August 2020, the FASB issued ASU No. 2020-06,
Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own
Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This amends the ASC 815
Derivatives and Hedging—Contracts in Entity’s Own Equity to simplify the guidance on (1) accounting for convertible instruments,
and (2) the derivatives scope exception for contracts in an entity’s own equity. The guidance on earnings per share (“EPS”)
has also been amended to simplify the calculations and make them more internally consistent. The Company adopted this new standard on
January 1, 2024. The new standard had no impact on the Company’s condensed consolidated financial statements.
Recently Issued Accounting Standards
The Company does not believe that any recently
issued but not yet effective accounting pronouncements will have a material effect on the accompanying unaudited condensed consolidated
financial statements.
3.
LICENSE AND SUPPLY AGREEMENT WITH TORAY INDUSTRIES
On
October 23, 2023, the Company and Toray entered into an Amended and Restated License Agreement (the “New Toray License Agreement”)
and a Master Supply Agreement (the “New Toray Supply Agreement”). Under the New Toray License Agreement, the Company continues
to license from Toray intellectual property rights needed to manufacture single-use test cartridges, and the Company has received the
right to sublicense certain Toray intellectual property to Sanyoseiko in connection with Sanyoseiko’s ongoing agreement with the
Company to manufacture its Symphony device and cartridges (including in connection with the Company’s clinical trials). In addition,
the New Toray License Agreement provides for the transfer of certain technology related to the cartridges to Sanyoseiko. The royalty
payments payable by the Company to Toray have been reduced under the New Toray License Agreement from 15% to 7.5% (or less in certain
circumstances) of net sales of certain cartridges for a term of 10 years. A 50% reduction in the royalty rate applies upon expiry of
applicable Toray patents on a product-by-product and country-by-country basis. The New Toray License Agreement contemplates that applicable
royalty payment obligations from the Company to Toray for other products will be determined separately by the parties in the future.
There were no sales of or revenues from the cartridges during the three month periods ended March 31, 2024 and 2023.
Under
the New Toray Supply Agreement, Toray is manufacturing (through its wholly owned subsidiary Kamakura Techno- Science, Inc.) certain product
intermediate components for use in cartridges being manufactured for the Company by Sanyoseiko. These cartridges made using Toray intermediates
are for the purpose of obtaining FDA approval and not for commercial sale. The New Toray Supply Agreement has a term ending on the earlier
of October 23, 2025 or the date that the Company obtains FDA approval for its product, and may be extended for up to six months by mutual
agreements of the parties. If FDA approval is obtained, Sanyoseiko will be required to manufacture the intermediates and cartridges under
a separate supply agreement between the Company and Sanyoseiko.
At
March 31, 2024 and 2023, there were no amounts accrued related to the New Toray License Agreement.
4.
WARRANTS
The
following table summarizes information with regard to warrants outstanding at March 31, 2024:
| |
Shares | | |
Exercisable for | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Life (in Years) | |
January 2024 Common Stock Warrants | |
| 2,692,308 | | |
Common Stock | |
$ | 1.30 | | |
| 4.8 | |
January 2024 Placement Agent Warrants | |
| 188,462 | | |
Common Stock | |
$ | 1.625 | | |
| 4.8 | |
January 2024 Prefunded Warrants | |
| 1,243,000 | | |
Common Stock | |
$ | 0.0001 | | |
| – | |
August 2023 Common Stock Warrants | |
| 216,000 | | |
Common Stock | |
$ | 7.365 | | |
| 4.4 | |
August 2023 Placement Agent Warrants | |
| 15,120 | | |
Common Stock | |
$ | 9.2063 | | |
| 4.4 | |
Class A Warrants | |
| 124,200 | | |
Common Stock | |
$ | 140.00 | | |
| 2.6 | |
Class B Warrants | |
| 3,770 | | |
Common Stock | |
$ | 200.00 | | |
| 2.6 | |
Other Pre-2024 Common Stock Warrants | |
| 40,594 | | |
Common Stock | |
$ | 64.73 | | |
| 1.9 | |
January
2024 Common Stock Warrants, January 2024 Placement Agent Warrants and January 2024 Prefunded Warrants
On
January 2, 2024, the Company sold in a public offering (such transaction, the “January 2024 Offering”) (i) 537,768 shares
of the Company’s common stock, and (ii) prefunded warrants to purchase up to an aggregate 2,154,540 shares of common
stock (the “Prefunded Warrants”). The Shares and Prefunded Warrants were sold together with warrants to purchase up to an
aggregate of 2,692,308 shares of Common Stock at an exercise price of $1.30 per share (the “January 2024 Warrants”).
The combined public offering price was $1.30 per share of Common Stock and related January 2024 Warrant and $1.2999 per Prefunded
Warrant and related January 2024 Warrant.
The
Prefunded Warrants are immediately exercisable and may be exercised at any time until all of the Prefunded Warrants are exercised in
full. The January 2024 Warrants are exercisable immediately upon issuance for a period of five years following the date of issuance.
Pursuant
to an engagement letter, dated as of August 7, 2023, as amended October 11, 2023 (the “Placement Agent Engagement Letter”),
by and between the Company and the H.C. Wainwright & Co., LLC, or the placement agent,
the Company paid the placement agent a total cash fee of $245,000 equal to 7.0% of the gross proceeds received in the January
2024 Offering. The Company also paid the placement agent in connection with the January Offering a management fee of $35,000 equal
to 1.0% of the gross proceeds raised in the January 2024 Offering and certain expenses incurred in connection with the January Offering.
In addition, the Company issued to the placement agent, warrants to purchase up to an aggregate 188,462 shares of common stock
(the “January 2024 Placement Agent Warrants”), which represents 7.0% of the aggregate number of shares of common stock
and Prefunded Warrants sold in the January 2024 Offering. The January 2024 Placement Agent Warrants have substantially the same terms
as the January 2024 Warrants, except that the January 2024 Placement Agent Warrants have an exercise price equal to $1.6250, or 125%
of the offering price per share of common stock and related January 2024 Warrant sold in the January Offering and expire on the fifth
anniversary from the date of the commencement of sales in the January 2024 Offering.
As
of March 31, 2024, 911,540 of the Prefunded Warrants had been exercised, and between March 31, 2014 and the date of this filing (May
15, 2024), an additional 216,000 of the Prefunded Warrants were exercised.
5.
STOCK COMPENSATION
Stock
Incentive Plans
In
2018, the Company adopted the 2018 Stock Incentive Plan (the “2018 Plan”) for employees, consultants, and directors. The
2018 Plan, which is administered by the Board of Directors, permits the Company to grant incentive and nonqualified stock options for
the purchase of common stock, and restricted stock awards. The maximum number of shares reserved for issuance under the 2018 Plan is
31,472. At March 31, 2024, there were 13,113 shares available for grant under the 2018 Plan.
On
July 6, 2021, the Company’s board of directors and stockholders approved and adopted the Bluejay Diagnostics, Inc. 2021 Stock Plan
(the “2021 Plan”). A total of 98,000 shares of common stock were approved to be initially reserved for issuance under the
2021 Stock Plan. At March 31, 2024, there were 40,377 shares available for grant under the 2021 Plan.
Stock
Award Activity
The
following table summarizes the status of the Company’s non-vested restricted stock awards for the three months ended March 31,
2024:
| |
Non-vested Restricted Stock Awards | |
| |
Number of Shares | | |
Weighted Average Grant Date Fair Value | |
Outstanding at December 31, 2023 | |
| 7,875 | | |
$ | 10.96 | |
Granted | |
| - | | |
| - | |
Vested | |
| (6,875 | ) | |
| 8.30 | |
Forfeited | |
| - | | |
| - | |
Outstanding at March 31, 2024 | |
| 1,000 | | |
$ | 25.80 | |
In
February 2023, the Company issued 18,734 fully vested restricted stock units to certain employees in lieu of cash to satisfy their 2022
bonuses of which 6,546 shares were withheld for tax liabilities with a fair value of $57,588. The number of restricted stock unit awards
issued were determined based on the approved bonus amount divided by the market price of the Company’s common stock on the date
of grant. The value of fully vested restricted stock unit awards issued is recorded as stock compensation expense on the date of grant
with a reversal of the related accrued bonus recorded in 2022.
The
following is a summary of stock option activity for the three months ended March 31, 2024:
| |
Number of Stock Options | | |
Weighted Average Exercise Price Per Share | | |
Weighted Average Remaining Contractual Life in Years | | |
Aggregate Intrinsic Value | |
Outstanding at December 31, 2023 | |
| 29,770 | | |
$ | 36.51 | | |
| 6.5 | | |
$ | - | |
Granted | |
| - | | |
| - | | |
| - | | |
| - | |
Exercised | |
| - | | |
| - | | |
| - | | |
| - | |
Cancelled and forfeited | |
| - | | |
| - | | |
| - | | |
| - | |
Outstanding at March 31, 2024 | |
| 29,770 | | |
$ | 36.51 | | |
| 6.3 | | |
$ | - | |
Exercisable at March 31, 2024 | |
| 26,209 | | |
$ | 36.51 | | |
| 6.3 | | |
$ | - | |
There
were no options granted during the three months ended March 31, 2024
The weighted average grant date fair value of options granted during
the three months ended March 31, 2023 was $0.44 per share. The Company calculated the grant-date fair value of stock option awards granted
during the three months ended March 31, 2023 using the Black-Scholes model with the following assumptions:
Risk-free interest rate | |
| 3.63 | % |
Expected dividend yield | |
| 0.00 | % |
Volatility factor | |
| 108.78 | % |
Expected life of option (in years) | |
| 6.0 | % |
Stock-Based
Compensation Expense
For
the three months ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense as follows:
| |
Three Months Ended March 31, | |
| |
2024 | | |
2023 | |
Research and development | |
$ | 4,845 | | |
$ | 44,845 | |
General and administrative | |
| 7,029 | | |
| 159,584 | |
Sales and marketing | |
| - | | |
| 15,160 | |
Total stock-based compensation | |
$ | 11,874 | | |
$ | 219,589 | |
At March 31, 2024, there was approximately
$12,609 of unrecognized compensation expense related to non-vested stock option awards that are expected to be recognized over a weighted-average
period of 0.91 years. At March 31, 2024, there was approximately $6,331 of unrecognized compensation expense related to non-vested restricted
stock awards that are expected to be recognized over a weighted-average period of 0.50 years.
6.
RELATED PARTY TRANSACTIONS
NanoHybrids,
LLC
In December 2021, the Company entered into an agreement with NanoHybrids,
LLC (“NanoHybrids”) to utilize the Company’s research and development staff and laboratory facility when available to
perform work for NanoHybrids. Any hours worked by Company employees for NanoHybrids are billed to NanoHybrids at a bill rate of the respective
employee’s fully burdened personnel cost plus 10%. Additionally, the Company may purchase certain lab supplies for NanoHybrids and
rebill these costs to NanoHybrids. NanoHybrids is majority owned by the Company’s Chief Technology Officer. The table below summarizes
the amounts earned and due from NanoHybrids as of and for the three-month periods’ ended March 31, 2024 and 2023, and balances due
as of March 31, 2024 and December 31, 2023:
| |
Three Months Ended March 31, | |
| |
2024 | | |
2023 | |
Income from NanoHybrids included in Other Income | |
$ | 73,591 | | |
$ | 95,798 | |
Cash receipts from NanoHybrids | |
$ | - | | |
$ | 19,731 | |
| |
As of | |
| |
March 31, 2024 | | |
December 31, 2023 | |
Amounts receivable from NanoHybrids included in Prepaids and Other Current Assets | |
$ | 73,591 | | |
$ | 41,269 | |
7.
PROPERTY AND EQUIPMENT
Property
and equipment consisted of the following at March 31, 2024 and December 31, 2023:
| |
Depreciable lives | |
March 31, 2024 | | |
December 31, 2023 | |
Construction-in-process | |
| |
$ | 1,088,255 | | |
$ | 1,052,822 | |
Furniture, fixtures, and equipment | |
3-5 years | |
| 141,164 | | |
| 141,164 | |
Software | |
3-5 years | |
| 4,457 | | |
| 4,457 | |
Lab equipment | |
3-5 years | |
| 1,287,783 | | |
| 1,287,783 | |
Leasehold improvements | |
Shorter of useful life or life of lease | |
| 43,231 | | |
| 43,231 | |
| |
| |
| 2,564,890 | | |
| 2,529,457 | |
Less: accumulated depreciation | |
| |
| (1,263,430 | ) | |
| (1,243,716 | ) |
Property and equipment, net | |
| |
$ | 1,301,460 | | |
$ | 1,285,741 | |
The Company reviews long-lived assets for impairment
when events, expectations, or changes in circumstances indicate that the asset’s carrying value may not be recoverable. As a result
of this review in 2023, the Company revised the useful life of certain lab equipment in the first quarter of 2023 due to a change in
expectations of the time the equipment will be used which resulted in approximately $45,000 of additional depreciation recorded in the
three months ended March 31, 2023.
8.
LEASES
The
Company has lease arrangements for office, laboratory space and copiers. A summary of supplemental lease information is as follows:
| |
Three Months Ended | |
| |
March 31, 2024 | | |
March 31, 2023 | |
Weighted average remaining lease term – operating leases (in years) | |
| 2.7 | | |
| 3.5 | |
Weighted average remaining lease term – finance leases (in years) | |
| 3.9 | | |
| 4.8 | |
Weighted average discount rate | |
| 7.0 | % | |
| 7.0 | % |
Operating cash flows from operating leases | |
$ | 44,214 | | |
$ | 43,564 | |
Operating cash flows from finance leases | |
$ | 4,807 | | |
$ | 1,202 | |
A
summary of the Company’s lease assets and liabilities are as follows:
| |
March 31, 2024 | | |
December 31, 2023 | |
Operating lease right-of-use asset | |
$ | 298,655 | | |
$ | 333,267 | |
Finance lease asset – property & equipment, net | |
| 13,970 | | |
| 15,152 | |
Total lease assets | |
| 312,625 | | |
| 348,419 | |
Current portion of operating lease liability | |
| 145,811 | | |
| 162,990 | |
Current portion of finance lease liability included in accrued expenses | |
| 4,807 | | |
| 4,807 | |
Non-current portion of operating lease liabilities | |
| 170,703 | | |
| 189,987 | |
Non-current portion of finance lease liabilities included in other non-current
liabilities | |
| 11,407 | | |
| 12,321 | |
Total lease liabilities | |
$ | 332,728 | | |
$ | 370,105 | |
A
summary of the Company’s estimated operating lease payments are as follows:
Year | |
| |
2024 (1) | |
$ | 120,812 | |
2025 | |
| 100,000 | |
2026 | |
| 100,000 | |
2027 | |
| 25,000 | |
2028 | |
| - | |
Thereafter | |
| - | |
Total future lease payments | |
| 345,812 | |
Less: Imputed interest | |
| 29,298 | |
Present value of lease liability | |
$ | 316,514 | |
9.
COMMITMENTS AND CONTINGENCIES
Minimum
Royalties
As required under the License Agreement (see Note 3), following the
first sale of Cartridges, the Company will also make royalty payments to Toray equal to 7.5% of the net sales of the Cartridges for a
term of 10 years. A 50% reduction in the royalty rate applies upon expiry of applicable Toray patents on a product-by-product and country-by-country
basis. There were no sales of or revenues from the Cartridges through March 31, 2024.
Indemnification
The
Company has certain agreements with service providers with which it does business that contain indemnification provisions pursuant to
which the Company typically agrees to indemnify the party against certain types of third-party claims. The Company accrues for known
indemnification issues when a loss is probable and can be reasonably estimated. The Company would also accrue for estimated incurred
but unidentified indemnification issues based on historical activity. As the Company has not incurred any indemnification losses to date,
there were no accruals for or expenses related to indemnification issues for any period presented.
10.
SUPPLEMENTAL BALANCE SHEET INFORMATION
Prepaid
expenses and other current assets consist of the following:
| |
March 31, 2024 | | |
December 31, 2023 | |
Prepaid insurance | |
$ | 37,090 | | |
$ | 136,342 | |
Vendor prepayments | |
| 538,019 | | |
| 558,959 | |
Prepaid other | |
| 213,469 | | |
| 51,962 | |
Total prepaid expenses and other current assets | |
$ | 788,578 | | |
$ | 747,263 | |
Accrued
expenses and other current liabilities consist of the following:
| |
March 31, 2024 | | |
December 31, 2023 | |
Accrued personnel costs | |
$ | 519,377 | | |
$ | 566,087 | |
Good received but unpaid | |
| 8,066 | | |
| 78,579 | |
Accrued expenses for CFO separation agreement | |
| 20,000 | | |
| 160,000 | |
Accrued legal fees | |
| 107,570 | | |
| 157,670 | |
Accrued clinical trial expenses | |
| 350,620 | | |
| - | |
Accrued other | |
| 102,472 | | |
| 154,575 | |
Total accrued expenses and other current liabilities | |
$ | 1,108,105 | | |
$ | 1,116,911 | |
ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You
should read the following discussion and analysis of our financial condition and results of operations in conjunction with the unaudited
condensed consolidated financial statements and the related notes appearing elsewhere in this Form 10-Q. This discussion contains forward-looking
statements reflecting our current expectations that involve risks and uncertainties. Actual results and the timing of events could differ
materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under “Risk
Factors” and elsewhere in this Form 10-Q.
Overview
We
are a clinical-stage medical diagnostics company developing rapid tests using whole blood on our Symphony platform (“Symphony”)
to improve patient outcomes in critical care settings. Our Symphony technology platform is an exclusively licensed, patented system that
consists of a mobile device and single-use test cartridges that if cleared, authorized, or approved by the U.S. Food and Drug Administration
(“FDA”), can provide a solution to a significant market need in the United States. Clinical trials indicate Symphony produces
results in less than 20 minutes for intensive care units and emergency rooms, where rapid and reliable results are required.
Since
inception, we have incurred net losses from operations each year and we expect to continue to incur losses for the foreseeable future.
We incurred net losses of approximately $2.3 million and $2.5 million for the three months ended March 31, 2024 and 2023, respectively.
We had negative cash flow from operating activities of approximately $2.3 million and $2.9 million for the three months ended March 31,
2024 and 2023, respectively, and had an accumulated deficit of approximately $29.2 million as of March 31, 2024.
As further described below under “Liquidity and Going Concern
Uncertainty” as of March 31, 2024, the Company possessed cash and cash equivalents of approximately $2.7 million, while having current
liabilities of approximately $1.5 million. During the quarter ended March 31, 2024, the Company’s net cash used in operating activities
approximately $2.3 million. The Company will need to raise a material amount of additional capital in the imminent near-term to continue
as a going concern, and that absent such near-term funding, it will likely run out of available cash resources in the near-term. If
we are unable to obtain financing in the near-term, or otherwise consummate strategic alternatives, we could determine to undertake a
process of liquidation under U.S. bankruptcy laws.
Results
of Operations
Comparison
of the Three Months Ended March 31, 2024 and 2023
The
following table sets forth our results of operations for the three months ended March 31, 2024 and 2023:
| |
Three Months Ended March 31, | |
| |
2024 | | |
2023 | |
Operating expenses: | |
| | |
| |
Research and development | |
| 1,334,796 | | |
| 1,354,549 | |
General and administrative | |
| 1,086,884 | | |
| 1,176,977 | |
Sales and marketing | |
| 6,426 | | |
| 148,046 | |
Total operating expenses | |
| 2,428,105 | | |
| 2,679,572 | |
| |
| | | |
| | |
Operating loss | |
| (2,428,105 | ) | |
| (2,679,572 | ) |
| |
| | | |
| | |
Other income: | |
| | | |
| | |
Other income, net | |
| 99,460 | | |
| 139,729 | |
Total other income | |
| 99,640 | | |
| 139,729 | |
Net loss | |
$ | (2,328,465 | ) | |
$ | (2,539,843 | ) |
Research
and Development
Research and development expenses for the three months ended March
31, 2024 were approximately $1.3 million as compared to approximately $1.4 million for the same period in 2023. The slight decrease in
research and development expenses was primarily due to a reduction in technology transfer efforts which offset increased clinical trial
expenses. We expect future research and development expenses to be focused on costs specifically associated with our clinical trial program
supporting our regulatory strategy, technology transfer efforts and any necessary manufacturing improvements.
General
and Administrative
General and administrative expenses for the three months ended March
31, 2024, were approximately $1.1 million as compared to approximately $1.2 million for the comparable period in 2023. The minor decrease
in general and administrative expenses is due to continued efforts to preserve capital by limiting our investment in infrastructure and
reducing professional services commensurate with our commercialization timeline. We expect to monitor and continue to pare our general
and administrative spend, as necessary, to optimize operational alignment.
Sales
and Marketing
Sales and marketing expenses for the three months ended March 31, 2024
were approximately $6,500 as compared to approximately $148,000 for the comparable period in 2023. The decrease in sales and marketing
expenses was due to a reduction in spending in all sales and marketing efforts.
Other
Income, net
Other
income, net for the three months ended March 31, 2024 was approximately $100,000 as compared to $140,000 for the same periods in 2023.
The decrease in net other income was primarily due to lower interest income due to a reduction in our cash balance resulting in a decrease
of approximately $12,000 and a decrease of approximately $22,000 in related party income from NanoHybrids.
Liquidity
and Going Concern Uncertainty
Our operations to date have been funded primarily
through the proceeds of (i) our initial public offering (the “IPO”) in November 2021 (the “IPO Date”), (ii) the
registered direct offering of common stock and concurrent private placement of warrants that we completed on August 28, 2023, and (iii)
the public offering of common stock and warrants that we completed on January 2, 2024. As of March 31, 2024, the Company possessed cash
and cash equivalents of approximately $2.7 million, while having current liabilities of approximately $1.5 million. During the quarter
ended March 31, 2024, the Company’s net cash used in operating activities was approximately $2.3 million. The Company expects that
it will need to raise a material amount of additional capital in the imminent near-term to continue as a going concern, and that absent
such near-term funding, it will likely run out of available cash resources in the near-term
We continue to develop the Symphony device and
its first test for the measurement of IL-6, including conducting clinical trials to obtain additional data to support a submission to
obtain FDA clearance of the Symphony device. However, our ability to continue these activities and continue operations (both over the
next 12 months and in the near-term) is dependent on the Company obtaining additional capital in the near-term. As a result of our lack
of cash, we have slowed the timeline of our clinical trial work to preserve cash resources in the near-term, and we expect that this
will delay our Symphony platform regulatory submission timeline until 2025. If we fail to obtain additional financing in the near-term,
this timeline could be delayed further, and we could be forced to abandon such activities entirely and cease operations, with the possible
loss of such properties or assets.
As
a result of the foregoing, we are actively exploring potential opportunities to raise additional capital in the near-term to fund our
operations. To date, our board of directors has not been able to identify alternatives that it believes to be viable. There can be no
assurance that such additional capital will be available on a timely basis or on acceptable terms. We currently do not have any contracts
or commitments for additional financing. In addition, any additional equity financing may involve substantial dilution to the Company’s
existing stockholders. If we are unable to obtain financing in the near-term, our board of directors could determine to cause the Company
to undertake a process of liquidation under Chapter 7 of applicable U.S. bankruptcy laws. In such event, we do not currently expect that
holders of shares of our common stock would recoup any material value in such process.
Summary
Statement of Cash Flows
The
following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented.
| |
Three Months Ended March 31, | |
| |
2024 | | |
2023 | |
Cash proceeds (used in) provided by: | |
| | |
| |
Operating activities | |
$ | (2,296,076 | ) | |
$ | (2,933,607 | ) |
Investing activities | |
| (35,433 | ) | |
| (340,669 | ) |
Financing activities | |
| 2,784,162 | | |
| (58,803 | |
Net increase (decrease) in cash and cash equivalents | |
$ | 452,653 | | |
$ | (3,333,079 | ) |
Net
cash used in operating activities
During the three months ended March 31, 2024,
we used approximately $2.3 million in cash for operating activities, a decrease of approximately $0.6 million as compared to approximately
$2.9 million for the same period in 2023. The decrease in net cash used in operating activities was primarily due to a decrease in personnel
costs and product development costs.
Net
cash used in investing activities
During
the three months ended March 31, 2024, we used approximately $35,000 in cash for investing activities, a decrease of approximately $306,000
as compared to the same period in 2023. The decrease in net cash used in investing activities was due to limited purchasing of manufacturing
equipment.
Net
cash used in financing activities
During the three months ended March 31, 2024,
we raised approximately $2.8 million in cash through financing activities, an increase of approximately $2.8 million as compared to the
same period in 2023. The increase in net cash generated by financing activities was due our public offering on January 2, 2024.
Recently
Adopted Accounting Standards
See
Note 2 to our condensed consolidated financial statements (under the caption “Recently Adopted Accounting Standards”).
Emerging
Growth Company and Smaller Reporting Company Status
We
are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). Under the JOBS Act,
emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until
such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or
revised accounting standards that have different effective dates for public and private companies until the earlier of the date that
we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided
in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the
new or revised accounting pronouncements as of public company effective dates. We are using the extended transition period for any other
new or revised accounting standards during the period in which we remain an emerging growth company.
We
will remain an emerging growth company until the earliest of (i) the last day of our first fiscal year (a) following the fifth anniversary
of the completion of IPO (November 2021), (b) in which we have total annual gross revenues of at least $1.07 billion or (c) in which
we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds
$700 million as of the prior June 30th and (ii) the date on which we have issued more than $1 billion in non-convertible debt
securities during the prior three-year period.
We
are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates is less than $700 million
and our annual revenue is less than $100 million during the most recently completed fiscal year. We may continue to be a smaller
reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our
annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by
non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth
company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements
in our Annual Reports on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure
obligations regarding executive compensation.
JOBS
Act Accounting Election
The
JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section
7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an “emerging
growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised
accounting standards on the relevant dates on which adoption of such standards is required for other public companies.
We
have implemented all new accounting pronouncements that are in effect and may impact our financial statements and we do not believe that
there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or
results of operations.
Item
3. Quantitative and Qualitative Disclosures About Market Risk
We
are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as Amended (the “Exchange Act”)
and are not required to provide the information required under this item.
Item
4. Controls and Procedures
(a)
Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting
We
conducted an evaluation under the supervision and with the participation of our management, including our President and Chief Executive
Officer (who serves as our principal executive officer and principal financial officer), regarding the effectiveness of our disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this
report. Based on this evaluation, our President and Chief Executive Officer concluded that our disclosure controls and procedures were
effective as of March 31, 2024. We continue to review our disclosure controls and procedures and may from time to time make changes aimed
at enhancing their effectiveness and to ensure that our systems evolve with our Company’s business. A control system, no matter
how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.
(b)
Changes in Internal Control Over Financial Reporting
There
was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that
occurred during the quarter ended March 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal
control over financial reporting.
PART
II - OTHER INFORMATION
Item
1. Legal Proceedings
From
time to time in the ordinary course of our business, we may be involved in legal proceedings, the outcomes of which may not be determinable.
The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result
in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able
to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and
estimable. We have insurance policies covering potential losses where such coverage is cost effective.
We
are not at this time involved in any legal proceedings.
Item
1A. Risk Factors
For
a discussion of potential risks or uncertainties, see “Risk Factors” in the Company’s 2023 annual report on Form 10-K
on file with the SEC. The following disclosures supplement such Risk Factors, and should be read in conjunction therewith:
Additional
Risks Related to Our Financial Condition and Capital Requirements
To
remain a going concern, we are in need of imminent material additional capital and absent our ability to raise such material capital
in the imminent near-term, we may be required to undertake a process of liquidation under U.S. bankruptcy laws, which we expect would
holders of our common stock not recouping any material value for their shares.
As of March 31, 2024, we possessed cash and cash equivalents of approximately
$2.7 million, while having current liabilities of approximately $1.5 million. During the quarter ended March 31, 2024, our net cash used
in operating activities was approximately $2.3 million, and we will need to raise a material amount of additional capital in the imminent
near-term to continue as a going concern, and that absent such near-term funding, we will likely run out of available cash resources in
the near-term. Our board of directors has been exploring potential pathways for material financing, or other strategic alternatives, and
to date, the board of directors has not been able to identify alternatives that it believes to be viable. If
we are unable to obtain financing in the imminent future, our board of directors could determine to cause the Company to undertake a process
of liquidation under Chapter 7 of applicable U.S. bankruptcy laws. In such event, we do not currently expect that holders of shares of
our common stock would recoup any material value in such process.
In
addition to our current non-compliance with Nasdaq’s $1.00 minimum bid price requirement, a further decline in the price of our
common stock could cause us to be delisted by Nasdaq on that basis.
In
addition to Nasdaq’s $1.00 per share bid price requirement, we are also required under Nasdaq rules to maintain a market value
of our publicly held securities of at least $1 million. As of the close of business on May 9, 2024, the market value of our publicly
held common stock (which is our only outstanding class of securities) was approximately $1.25 million. If the value of our publicly held
common stock declines below $1 million, we would also be subject to Nasdaq delisting proceedings on that basis.
Item
2. Unregistered Sales of Equity Securities and Use of Proceeds
None
Item
3. Defaults Upon Senior Securities
None.
Item
4. Mine Safety Disclosures
Not
applicable.
Item
5. Other Information
None.
Item
6. Exhibits
INDEX
TO EXHIBITS
(1) |
The certifications on Exhibit
32 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability
of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the
Exchange Act. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Bluejay
Diagnostics, Inc.
SIGNATURE |
|
TITLE |
|
DATE |
|
|
|
|
|
/s/
Neil Dey |
|
President, Chief Executive Officer and Director |
|
May 15, 2024 |
Neil Dey |
|
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) |
|
|
|
|
|
|
|
0.99
2.49
1018755
2359376
false
--12-31
Q1
0001704287
0001704287
2024-01-01
2024-03-31
0001704287
2024-05-01
0001704287
2024-03-31
0001704287
2023-12-31
0001704287
2023-01-01
2023-03-31
0001704287
us-gaap:CommonStockMember
2023-12-31
0001704287
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001704287
us-gaap:RetainedEarningsMember
2023-12-31
0001704287
us-gaap:CommonStockMember
2024-01-01
2024-03-31
0001704287
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-03-31
0001704287
us-gaap:RetainedEarningsMember
2024-01-01
2024-03-31
0001704287
bjdx:PreFundedWarrantsMember
2024-01-01
2024-03-31
0001704287
us-gaap:CommonStockMember
2024-03-31
0001704287
us-gaap:AdditionalPaidInCapitalMember
2024-03-31
0001704287
us-gaap:RetainedEarningsMember
2024-03-31
0001704287
us-gaap:CommonStockMember
2022-12-31
0001704287
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001704287
us-gaap:RetainedEarningsMember
2022-12-31
0001704287
2022-12-31
0001704287
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001704287
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001704287
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001704287
us-gaap:CommonStockMember
2023-03-31
0001704287
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001704287
us-gaap:RetainedEarningsMember
2023-03-31
0001704287
2023-03-31
0001704287
bjdx:NasdaqStockMarketLLCMember
2024-03-31
0001704287
bjdx:NasdaqStockMarketLLCMember
2024-01-01
2024-03-31
0001704287
2024-02-28
2024-02-28
0001704287
2024-05-09
0001704287
2024-05-09
2024-05-09
0001704287
us-gaap:IPOMember
2024-03-31
0001704287
bjdx:OptionsToPurchaseCommonStockMember
2024-01-01
2024-03-31
0001704287
bjdx:OptionsToPurchaseCommonStockMember
2023-01-01
2023-03-31
0001704287
us-gaap:RestrictedStockUnitsRSUMember
2024-01-01
2024-03-31
0001704287
us-gaap:RestrictedStockUnitsRSUMember
2023-01-01
2023-03-31
0001704287
bjdx:WarrantsForCommonStockMember
2024-01-01
2024-03-31
0001704287
bjdx:WarrantsForCommonStockMember
2023-01-01
2023-03-31
0001704287
us-gaap:CommonClassAMember
2024-01-01
2024-03-31
0001704287
us-gaap:CommonClassAMember
2023-01-01
2023-03-31
0001704287
us-gaap:CommonClassBMember
2024-01-01
2024-03-31
0001704287
us-gaap:CommonClassBMember
2023-01-01
2023-03-31
0001704287
bjdx:FiveYearWarrantsForCommonStockMember
2024-01-01
2024-03-31
0001704287
bjdx:FiveYearWarrantsForCommonStockMember
2023-01-01
2023-03-31
0001704287
bjdx:PrefundedWarrantsForCommonStockMember
2024-01-01
2024-03-31
0001704287
bjdx:PrefundedWarrantsForCommonStockMember
2023-01-01
2023-03-31
0001704287
srt:MaximumMember
2023-10-23
2023-10-23
0001704287
srt:MinimumMember
2023-10-23
2023-10-23
0001704287
2023-10-23
2023-10-23
0001704287
bjdx:PrefundedWarrantsMember
2024-01-02
0001704287
bjdx:PrefundedWarrantsMember
2024-01-02
2024-01-02
0001704287
2024-01-02
0001704287
2024-01-02
2024-01-02
0001704287
bjdx:HCWainwrightCoLLCMember
2024-01-01
2024-03-31
0001704287
bjdx:January2024PlacementAgentWarrantsMember
2024-03-31
0001704287
bjdx:January2024PlacementAgentWarrantsMember
2024-01-01
2024-03-31
0001704287
us-gaap:WarrantMember
2024-01-01
2024-03-31
0001704287
bjdx:January2024CommonStockWarrantsMember
2024-03-31
0001704287
bjdx:January2024CommonStockWarrantsMember
2024-01-01
2024-03-31
0001704287
bjdx:January2024PrefundedWarrantsMember
2024-03-31
0001704287
bjdx:January2024PrefundedWarrantsMember
2024-01-01
2024-03-31
0001704287
bjdx:August2023CommonStockWarrantsMember
2024-03-31
0001704287
bjdx:August2023CommonStockWarrantsMember
2024-01-01
2024-03-31
0001704287
bjdx:August2023PlacementAgentWarrantsMember
2024-03-31
0001704287
bjdx:August2023PlacementAgentWarrantsMember
2024-01-01
2024-03-31
0001704287
bjdx:ClassAWarrantsMember
2024-03-31
0001704287
bjdx:ClassAWarrantsMember
2024-01-01
2024-03-31
0001704287
bjdx:ClassBWarrantsMember
2024-03-31
0001704287
bjdx:ClassBWarrantsMember
2024-01-01
2024-03-31
0001704287
bjdx:OtherPre2024CommonStockWarrantsMember
2024-03-31
0001704287
bjdx:OtherPre2024CommonStockWarrantsMember
2024-01-01
2024-03-31
0001704287
bjdx:StockIncentivePlanTwoThousandAndEighteenMember
2024-03-31
0001704287
bjdx:TwoThousandTwentyOnePlanMember
2024-03-31
0001704287
2023-02-28
0001704287
bjdx:NonvestedStockOptionMember
2024-03-31
0001704287
bjdx:NonvestedStockOptionMember
2024-01-01
2024-03-31
0001704287
bjdx:NonVestedRestrictedStockAwardsMember
2024-03-31
0001704287
bjdx:NonVestedRestrictedStockAwardsMember
2024-01-01
2024-03-31
0001704287
us-gaap:RestrictedStockUnitsRSUMember
2023-12-31
0001704287
us-gaap:RestrictedStockUnitsRSUMember
2024-03-31
0001704287
2023-12-30
0001704287
2023-12-31
2023-12-31
0001704287
us-gaap:ResearchAndDevelopmentExpenseMember
2024-01-01
2024-03-31
0001704287
us-gaap:ResearchAndDevelopmentExpenseMember
2023-01-01
2023-03-31
0001704287
us-gaap:GeneralAndAdministrativeExpenseMember
2024-01-01
2024-03-31
0001704287
us-gaap:GeneralAndAdministrativeExpenseMember
2023-01-01
2023-03-31
0001704287
bjdx:SalesAndMarketingMember
2024-01-01
2024-03-31
0001704287
bjdx:SalesAndMarketingMember
2023-01-01
2023-03-31
0001704287
bjdx:NanoHybridsLLCMember
2021-01-01
2021-12-31
0001704287
bjdx:IncomeFromNanohybridsIncludedInOtherIncomeMember
2024-01-01
2024-03-31
0001704287
bjdx:IncomeFromNanohybridsIncludedInOtherIncomeMember
2023-01-01
2023-03-31
0001704287
bjdx:CashReceiptsFromNanohybridsMember
2024-01-01
2024-03-31
0001704287
bjdx:CashReceiptsFromNanohybridsMember
2023-01-01
2023-03-31
0001704287
us-gaap:ConstructionInProgressMember
2024-03-31
0001704287
us-gaap:ConstructionInProgressMember
2023-12-31
0001704287
srt:MinimumMember
us-gaap:FurnitureAndFixturesMember
2024-03-31
0001704287
srt:MaximumMember
us-gaap:FurnitureAndFixturesMember
2024-03-31
0001704287
us-gaap:FurnitureAndFixturesMember
2024-03-31
0001704287
us-gaap:FurnitureAndFixturesMember
2023-12-31
0001704287
srt:MinimumMember
us-gaap:SoftwareAndSoftwareDevelopmentCostsMember
2024-03-31
0001704287
srt:MaximumMember
us-gaap:SoftwareAndSoftwareDevelopmentCostsMember
2024-03-31
0001704287
us-gaap:SoftwareAndSoftwareDevelopmentCostsMember
2024-03-31
0001704287
us-gaap:SoftwareAndSoftwareDevelopmentCostsMember
2023-12-31
0001704287
srt:MinimumMember
bjdx:LabEquipmentMember
2024-03-31
0001704287
srt:MaximumMember
bjdx:LabEquipmentMember
2024-03-31
0001704287
bjdx:LabEquipmentMember
2024-03-31
0001704287
bjdx:LabEquipmentMember
2023-12-31
0001704287
us-gaap:LeaseholdImprovementsMember
2024-01-01
2024-03-31
0001704287
us-gaap:LeaseholdImprovementsMember
2024-03-31
0001704287
us-gaap:LeaseholdImprovementsMember
2023-12-31
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
(Subsections (a) and (b) of Section 1350,
Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of
the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned
officer of Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s
knowledge, that:
The quarterly report on Form 10-Q for
the quarter ended March 31, 2024 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material
respects, the financial condition and results of operations of the Company.
(Subsections (a) and (b) of Section 1350,
Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of
the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned
officer of Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s
knowledge, that:
The quarterly report on Form 10-Q for
the quarter ended March 31, 2024 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material
respects, the financial condition and results of operations of the Company.